With a target of mobilising $300 million over its first five years

目标是在头五年内筹集3亿美元

South Korea-based International Vaccine Institute (IVI) and the Government of Brazil have taken an important step toward establishing the Bridging Research Investment in Global Health Technology (BRIGHT) Fund.

韩国国际疫苗研究所（IVI）和巴西政府在建立全球卫生技术研究投资桥梁基金（BRIGHT）方面迈出了重要一步。

IVI and Brazil signed letters of intent supporting the establishment of the BRIGHT Fund, a multi-donor, country-led financing platform designed to accelerate health innovation and expand equitable access to life-saving technologies.

国际疫苗研究所（IVI）和巴西签署了支持建立BRIGHT基金的意向书，该基金是一个多捐助方、国家主导的融资平台，旨在加速健康创新并扩大公平获取拯救生命的技术。

The BRIGHT Fund is a multi-donor financing platform under development aimed at addressing persistent gaps in global health innovation. Despite growing scientific capacity in low- and middle-income countries, many promising innovations fail to reach populations and deliver health impact due to insufficient and fragmented financing and limited end-to-end development partnerships.

BRIGHT基金是一个正在开发中的多捐助方融资平台，旨在解决全球健康创新中长期存在的缺口问题。尽管低收入和中等收入国家的科研能力不断提升，但由于资金不足且分散，以及端到端开发合作伙伴关系有限，许多有前景的创新未能惠及人群并产生健康影响。

The BRIGHT Fund seeks to bridge this “valley of death” by providing sustained, milestone-based investment in the Global South to support the full pathway from research to commercialization and local production, while also fostering the growth of small- and medium-sized enterprises and supporting job creation and broader economic development..

BRIGHT基金旨在通过为全球南方提供持续的、基于里程碑的投资，弥合这一“死亡之谷”，支持从研究到商业化和本地生产的全过程，同时促进中小企业的成长，支持就业创造和更广泛的经济发展。

With a target of mobilising $300 million over its first five years, the BRIGHT Fund is expected to support the development and production of vaccines, therapeutics, diagnostics, and digital health innovations.

BRIGHT基金的目标是在头五年内筹集3亿美元，预计将支持疫苗、治疗药物、诊断技术以及数字健康创新的研发与生产。